Anti-Cancer Potential of Dehydrozingerone's Phenoxy-Acetamide Derivatives: Discovery of a Potent Lead with Dual Anti-Proliferative and Anti-Metastatic Activities

IF 4.5 2区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Bioorganic Chemistry Pub Date : 2025-03-27 DOI:10.1016/j.bioorg.2025.108413

Chetan Kumar , Anshurekha Dash , Rohit Singh , Tanzeeba Amin , Salil Suresh , Anindya Goswami , Ravindra S. Phatake

{"title":"Anti-Cancer Potential of Dehydrozingerone's Phenoxy-Acetamide Derivatives: Discovery of a Potent Lead with Dual Anti-Proliferative and Anti-Metastatic Activities","authors":"Chetan Kumar , Anshurekha Dash , Rohit Singh , Tanzeeba Amin , Salil Suresh , Anindya Goswami , Ravindra S. Phatake","doi":"10.1016/j.bioorg.2025.108413","DOIUrl":null,"url":null,"abstract":"<div><div>Herein, we report the design and synthesis of twenty-eight novel phenoxy-acetamide derivatives of dehydrozingerone (DHZ), aimed at exploring their potential as anticancer agents. The newly synthesized compounds were characterized using NMR, mass spectrometry, and HPLC. The in vitro anticancer activity was evaluated against MCF-7, HCT-116, and A549 cancer cell lines, where compounds 2, 4, 9, 14, 26, and 27 exhibited the highest potency, with IC50 values ranging from 3.52 to 9.93 μM. These promising molecules were further tested against PC3 and Panc1 cell lines, demonstrating strong anticancer effects. Selectivity index analysis revealed that compound 14 demonstrated the highest selectivity for PC3, while compound 2 consistently exhibited notable selectivity across multiple cancer cell lines, highlighting their potential for targeted therapy. Clonogenic assays confirmed that compound 2 significantly reduced the long-term proliferative capacity of HCT-116 and MCF-7 cells in a dose-dependent manner. Mechanistic studies revealed that compound 2 induced cell cycle arrest by modulating Cyclin D1, leading to altered BAX/Bcl-2 and PARP levels, caspase cascade activation, and apoptotic cell death. Additionally, compound 2 regulated epithelial-mesenchymal transition (EMT), as evidenced by downregulation of Snail and upregulation of E-cadherin and occludin in a dose-dependent manner. Furthermore, molecular docking and ADMET predictions support compound 2 as a promising lead for anticancer drug discovery.</div></div>","PeriodicalId":257,"journal":{"name":"Bioorganic Chemistry","volume":"159 ","pages":"Article 108413"},"PeriodicalIF":4.5000,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioorganic Chemistry","FirstCategoryId":"92","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0045206825002937","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Herein, we report the design and synthesis of twenty-eight novel phenoxy-acetamide derivatives of dehydrozingerone (DHZ), aimed at exploring their potential as anticancer agents. The newly synthesized compounds were characterized using NMR, mass spectrometry, and HPLC. The in vitro anticancer activity was evaluated against MCF-7, HCT-116, and A549 cancer cell lines, where compounds 2, 4, 9, 14, 26, and 27 exhibited the highest potency, with IC₅₀ values ranging from 3.52 to 9.93 μM. These promising molecules were further tested against PC3 and Panc1 cell lines, demonstrating strong anticancer effects. Selectivity index analysis revealed that compound 14 demonstrated the highest selectivity for PC3, while compound 2 consistently exhibited notable selectivity across multiple cancer cell lines, highlighting their potential for targeted therapy. Clonogenic assays confirmed that compound 2 significantly reduced the long-term proliferative capacity of HCT-116 and MCF-7 cells in a dose-dependent manner. Mechanistic studies revealed that compound 2 induced cell cycle arrest by modulating Cyclin D1, leading to altered BAX/Bcl-2 and PARP levels, caspase cascade activation, and apoptotic cell death. Additionally, compound 2 regulated epithelial-mesenchymal transition (EMT), as evidenced by downregulation of Snail and upregulation of E-cadherin and occludin in a dose-dependent manner. Furthermore, molecular docking and ADMET predictions support compound 2 as a promising lead for anticancer drug discovery.

Abstract Image

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Bioorganic Chemistry 生物-生化与分子生物学

CiteScore

9.70

自引率

3.90%

发文量

679

审稿时长

31 days

期刊介绍： Bioorganic Chemistry publishes research that addresses biological questions at the molecular level, using organic chemistry and principles of physical organic chemistry. The scope of the journal covers a range of topics at the organic chemistry-biology interface, including: enzyme catalysis, biotransformation and enzyme inhibition; nucleic acids chemistry; medicinal chemistry; natural product chemistry, natural product synthesis and natural product biosynthesis; antimicrobial agents; lipid and peptide chemistry; biophysical chemistry; biological probes; bio-orthogonal chemistry and biomimetic chemistry. For manuscripts dealing with synthetic bioactive compounds, the Journal requires that the molecular target of the compounds described must be known, and must be demonstrated experimentally in the manuscript. For studies involving natural products, if the molecular target is unknown, some data beyond simple cell-based toxicity studies to provide insight into the mechanism of action is required. Studies supported by molecular docking are welcome, but must be supported by experimental data. The Journal does not consider manuscripts that are purely theoretical or computational in nature. The Journal publishes regular articles, short communications and reviews. Reviews are normally invited by Editors or Editorial Board members. Authors of unsolicited reviews should first contact an Editor or Editorial Board member to determine whether the proposed article is within the scope of the Journal.